Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Insider Thomas Gad Sells 10,810 Shares

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) insider Thomas Gad sold 10,810 shares of the business’s stock in a transaction on Friday, March 7th. The shares were sold at an average price of $5.23, for a total value of $56,536.30. Following the completion of the sale, the insider now owns 202,721 shares of the company’s stock, valued at $1,060,230.83. This trade represents a 5.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Y-mAbs Therapeutics Trading Up 3.8 %

Shares of YMAB opened at $4.94 on Wednesday. The stock has a 50 day moving average of $6.22 and a 200 day moving average of $10.38. Y-mAbs Therapeutics, Inc. has a 12 month low of $4.25 and a 12 month high of $17.78. The company has a market capitalization of $223.38 million, a price-to-earnings ratio of -9.15 and a beta of 0.65.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The firm had revenue of $26.50 million during the quarter, compared to analysts’ expectations of $26.70 million. During the same period in the prior year, the business earned ($0.02) earnings per share. As a group, equities research analysts predict that Y-mAbs Therapeutics, Inc. will post -0.65 earnings per share for the current year.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Several large investors have recently added to or reduced their stakes in YMAB. Acorn Capital Advisors LLC purchased a new stake in Y-mAbs Therapeutics during the fourth quarter valued at about $22,408,000. Caligan Partners LP raised its position in Y-mAbs Therapeutics by 105.3% during the third quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock valued at $15,718,000 after purchasing an additional 613,175 shares in the last quarter. State Street Corp raised its position in Y-mAbs Therapeutics by 50.4% during the third quarter. State Street Corp now owns 1,209,781 shares of the company’s stock valued at $15,909,000 after purchasing an additional 405,169 shares in the last quarter. Infinitum Asset Management LLC purchased a new stake in Y-mAbs Therapeutics during the fourth quarter valued at about $1,218,000. Finally, Paradigm Biocapital Advisors LP raised its position in Y-mAbs Therapeutics by 3.7% during the fourth quarter. Paradigm Biocapital Advisors LP now owns 4,236,346 shares of the company’s stock valued at $33,171,000 after purchasing an additional 150,000 shares in the last quarter. Institutional investors own 70.85% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on YMAB shares. HC Wainwright reiterated a “buy” rating and set a $22.00 target price on shares of Y-mAbs Therapeutics in a research report on Monday, January 13th. Morgan Stanley cut their target price on Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating for the company in a research report on Wednesday, March 5th. Wedbush reissued an “outperform” rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a report on Monday, March 3rd. Truist Financial lowered their price target on Y-mAbs Therapeutics from $21.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday, March 5th. Finally, Bank of America lowered their price target on Y-mAbs Therapeutics from $14.00 to $12.00 and set a “neutral” rating for the company in a report on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $19.30.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.